Roy S. Herbst, MD, PhD: The REVEL trial compared docetaxel, a standard second-line lung cancer therapy, with docetaxel plus ramucirumab, the VEGFR2 antibody, and included both squamous and nonsquamous lung cancer. Actually, the toxicity results suggest that one could give the drug in both settings, and there was an improvement in survival across the board in both the squamous and nonsquamous settings. Off the top of my head, the hazard ratio was in the mid-0.8 range—not the highest ratio one has ever seen, but clinically and statistically significant.
There is some benefit. This drug was approved almost at the same time as nivolumab. Many people are, in the second-line setting, using nivolumab, which has relegated this regimen to the third-line setting, but I think that it is clearly better than docetaxel if one were going to use docetaxel, adding minimal additional side effects. I also believe that ramucirumab might have some role in immunotherapy in altering the microenvironment—in favor of the immune therapies working better.
Toxicities are managed in the usual ways. When you add ramucirumab to docetaxel, the main toxicity is still going to be neutropenia—probably only slightly exacerbated by the VEGF inhibitor—and certainly neuropathy. You would manage it with supportive care; treatment of febrile neutropenia, when that develops; and blood product repletion, if that’s needed. We’ve gotten pretty good at giving docetaxel. It’s a tough drug, but certainly very manageable.
In the second-line setting these days, most people would use immunotherapy unless they really have a reason not to. The reasons not to would be some sort of autoimmune disease, pneumonitis, psoriasis, something preexisting that would make you concerned about using an immune checkpoint inhibitor that would activate the immune system, or someone who is terribly symptomatic to the point where you are worried that the immunotherapy wouldn’t happen for more than 2 or 3 weeks before the patient needs something to be done for their symptoms. There, you would want the best
response you could get, and that would probably be with a docetaxel and ramucirumab combination.
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Traditional Medicare Supplemental Insurance and the Rise of Medicare Advantage
May 7th 2024Rising Medicare Advantage enrollment occurred alongside declines in enrollment in traditional Medicare with employer-sponsored supplemental coverage and traditional Medicare without supplemental coverage.
Read More
Following Roe v Wade Overturn, Research Focuses on Male Contraceptives
May 6th 2024Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.
Read More